3-[(2-环己基-2-羟乙基)氨基]-2,5-二氧代-1-(苯甲基)-4-咪唑啶庚酸 | 118675-50-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 3-[(2-环己基-2-羟乙基)氨基]-2,5-二氧代-1-(苯甲基)-4-咪唑啶庚酸
• 英文名称: 3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)hydantoin
• 英文别名: BW-A 868C；7-[1-benzyl-3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxoimidazolidin-4-yl]heptanoic acid
• CAS: 118675-50-6
• 化学式: C₂₅H₃₇N₃O₅
• mdl: MFCD00877696
• 分子量: 459.586
• InChiKey: YZJVWSKJHGEIBL-UHFFFAOYSA-N

物化性质

• 沸点：
  638.1±65.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO：>5 mg/mL，可溶

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  33
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• WGK Germany：
  3

文献信息

• DRUGS FOR IMPROVING THE PROGNOSIS OF BRAIN INJURY AND A METHOD OF SCREENING THE SAME
  申请人：Japan Science and Technology Agency

  公开号：EP1535629A1

  公开（公告）日：2005-06-01

  There are provided a compound for treatment or prevention of brain injury caused by diseases such as cerebrovascular disorder, brain degenerative disease and demyelinating disease and a method for screening the same. Brain injury in which prostaglandin D2 is participated is treated or prevented by inhibition of hematopoietic prostaglandin D synthase induced in microglia cell or macrophage of brain injury area by diseases such as cerebrovascular disorder, brain degenerative disease or demyelinating disease or by inhibition of activation of prostaglandin D receptor expressed in astroglia cell around the injured area. There is also provided a method of testing those pharmaceutical substances using a transgenic mouse in which human hematopoietic prostaglandin D synthase is expressed in large amounts.

  提供了一种用于治疗或预防脑血管疾病、脑变性疾病和脱髓鞘疾病等疾病引起的脑损伤的化合物及其筛选方法。 通过抑制脑血管疾病、脑变性疾病或脱髓鞘疾病等疾病在脑损伤区域的小胶质细胞或巨噬细胞中诱导的造血前列腺素 D 合成酶，或通过抑制损伤区域周围星形胶质细胞中表达的前列腺素 D 受体的活化，治疗或预防前列腺素 D2 参与的脑损伤。此外，还提供了一种利用大量表达人造血前列腺素 D 合酶的转基因小鼠检测这些药物的方法。
• NOVEL USES OF PROSTAGLANDIN D sb 2 /sb , PROSTAGLANDIN D sb 2 /sb AGONIST AND PROSTAGLANDIN D sb 2 /sb ANTAGONIST
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1547598A1

  公开（公告）日：2005-06-29

  The present invention provides novel use of PGD2, a PGD2 agonist and a PGD2 antagonist. More specifically, the present invention provides uses of PGD2 and a PGD2 agonist as eating promoter and use of a PGD2 antagonist as an eating inhibitor.

  本发明提供了 PGD2、PGD2 激动剂和 PGD2 拮抗剂的新用途。更具体地说，本发明提供了 PGD2 和 PGD2 激动剂作为进食促进剂的用途，以及 PGD2 拮抗剂作为进食抑制剂的用途。
• Drugs for improving prognosis of brain injury
  申请人：Japan Science and Technology Agency

  公开号：EP1598065A2

  公开（公告）日：2005-11-23

  A compound for treatment or prevention of brain injury caused by diseases such as cerebrovascular disorder, brain degenerative disease and demyelinating disease. The compound comprises an antagonist for the prostaglandin D receptor as an effective ingredient. Brain injury in which prostaglandin D2 is a factor is treated or prevented by inhibition of hematopoietic prostaglandin D synthase induced in microglia cell or macrophage of brain area by diseases such as cerebrovascular disorder, brain degenerative disease or demyelinating disease or by inhibition of activation of prostaglandin D receptor expressed in astroglia cell around the injured area.

  一种化合物，用于治疗或预防由脑血管疾病、脑变性疾病和脱髓鞘疾病等疾病引起的脑损伤。该化合物的有效成分包括前列腺素 D 受体拮抗剂。 通过抑制脑血管疾病、脑变性疾病或脱髓鞘疾病等疾病在脑区小胶质细胞或巨噬细胞中诱导的造血前列腺素 D 合成酶，或通过抑制损伤区周围星形胶质细胞中表达的前列腺素 D 受体的活化，治疗或预防以前列腺素 D2 为因素的脑损伤。
• Tape preparation of WT1 peptide cancer vaccine for transdermal administration
  申请人：NITTO DENKO CORPORATION

  公开号：US10195258B2

  公开（公告）日：2019-02-05

  The present invention provides a cancer vaccine tape preparation for inducing cellular immunity, comprising: a support, an adhesive layer comprising an adhesive disposed on one side of the support, wherein the adhesive layer carries a combination of: (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a first cellular immunity induction promoter. The tape preparation can provides high efficacy.

  本发明提供了一种用于诱导细胞免疫的癌症疫苗带制剂，包括 一个支架 由粘合剂组成的粘合剂层，粘合剂层设置在支撑物的一侧，其中粘合剂层携带以下物质的组合 (i) WT1 肽和/或修饰的 WT1 肽；以及 (ii) 第一细胞免疫诱导启动子。这种胶带制剂具有很高的功效。
• WT1 peptide cancer vaccine composition for mucosal administration
  申请人：NITTO DENKO CORPORATION

  公开号：US10206985B2

  公开（公告）日：2019-02-19

  The present invention provides a cancer vaccine composition for mucosal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.

  本发明提供了一种用于粘膜给药以诱导细胞免疫的癌症疫苗组合物，该组合物包含(i)WT1 肽和/或修饰的 WT1 肽；以及(ii)细胞免疫诱导促进剂。该组合物能有效诱导受试者产生抗癌细胞免疫。